“Catheter ablative therapy, one of the latest treatments, has allowed us to provide long-term elimination of A-Fib and its associated severe symptoms – the majority of our patients no longer need antiarrhythmic drug therapy and have a dramatic improvement in their quality of life.”

– Francis Marchlinski, MD
Director, Cardiac Electrophysiology Program
University of Pennsylvania Health System

Clinical Trials

Medtronic Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Trial CURE-AF Trial - Permanent Atrial Fibrillation CURE-AF Trial - Persistent Atrial Fibrillation

Penn's collective experience in the treatment of patients with AF culminated in our selection as the only center in the Philadelphia region (and one of only ten centers nationwide) to participate in this landmark clinical trial.

The purpose of the CURE-AF Trial is to evaluate the safety and effectiveness of the Medtronic Cardioblate® Surgical Ablation System at reestablishing the normal heart rhythm in patients with permanent AF or persistent AF requiring concomitant open heart surgery utilizing the modified Cox Maze III procedure.

The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs or coronary artery bypass graft (CABG) procedures.